2nd Operationalize: Expanded Access Programs Summit West

Across the West Coast, Expanded Access Programs are entering a new phase. More companies are launching EAPs earlier in development, supporting patients for longer durations, and extending access beyond the U.S. into increasingly complex global markets. What was once a reactive, exception-based activity is now a visible, repeatable function – bringing heightened expectations around governance, post-trial access, sustainability, and real-world insight generation, all while ensuring patients are not delayed or disadvantaged.

The 2nd Operationalize: Expanded Access Programs Summit West arrives at a critical moment. Purpose-built for West Coast biotech and pharma teams, this summit brings together senior leaders across Access, Medical Affairs, Clinical Operations, Regulatory, and Clinical Supply to share how EAPs are being designed, governed, and scaled in today’s environment.

Over three focused days, the summit tackles the most pressing questions facing EAP teams in 2026 – from navigating evolving U.S. and global regulatory expectations, to enabling providers and patient advocates, designing post-trial access strategies, managing long-duration and rare disease programs, and applying real-world insights without slowing access.

This is not a theoretical discussion. It is a peer-led, non-competitive forum for teams responsible for delivering access at scale – and for those shaping what Expanded Access must become next.

To know more visit: https://ter.li/gk0u1gt1